Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 118

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 118
---
, like WHO and NIH, NGOs, and governments, especially in regions with  
 high burdens of antibiotic-resistant infections. These partnerships can facilitate market access, drive adoption, and support public 
 health initiatives.                                                                                                                  |

<div align='center'>76</div>

With respect to Development of ARB combination therapy, our strategy includes:

| ● | Early Collaborative                                                                                                                
 Ventures: Initiate strategic collaborations with leading oncology-focused pharmaceutical companies early in the development cycle, 
 particularly following promising preclinical results or early-phase clinical trial success. These collaborations could encompass   
 licensing deals, co-development agreements, or joint ventures, aimed at leveraging external expertise and resources to accelerate  
 ARB’s progression through clinical development and regulatory pathways.                                                            |

| ● | Target High-Impact Indications:                                                                                                             
 Prioritize cancer indications where the tumor microenvironment (TME) significantly impacts treatment outcomes and where current therapeutic 
 options are limited. Focusing on these indications can potentially facilitate expedited regulatory approvals, such as orphan drug           
 status or breakthrough therapy designation, enhancing ARB’s attractiveness to potential partners and acquirers.                             |

| ● | Strategic Regulatory                                                                                                                 
 Engagement: Pursue early and continuous engagement with regulatory bodies to navigate the development process efficiently, utilizing 
 programs like the FDA’s Fast Track and Priority Review to shorten the timeline to market authorization.                              |

| ● | Robust IP Portfolio                                                                                                                    
 Development: Expand and protect the intellectual property landscape around main ARB patent, including its unique liposomal formulation 
 manufacturing methods and potential use cases across various solid tumors.                                                             |

| ● | Data Publication and                                                                                                          
 Presentation: Strategically release clinical trial results and other key data milestones at major oncology conferences and in 
 high-impact journals to maximize visibility and interest from the oncology community, investors, and potential acquirers.     |

| ● | Timely Exit Considerations:                                                                                                        
 Evaluate exit opportunities following pivotal Phase 2 data, which often serves as an inflection point in valuation for emerging    
 oncology therapies, balancing the potential for further value appreciation against the risks and costs of later-stage development. |

| ● | Expanding Therapeutic                                                                                                                
 Range: Broaden the scope of ARB’s development program to explore its potential across a diverse array of solid tumors,               
 capitalizing on the versatility of the liposomal formulation to address multiple facets of the TME. This expansion can significantly 
 enhance ARB’s market potential and long-term value.                                                                                  |

| ● | Enduring Partnerships                                                                                                                 
 and